400 Corporate Circle, Suite N
53 articles about PharmaJet
PharmaJet,® a company engineering Precision Delivery Systems™ that overcome the challenges of vaccines and pharmaceuticals delivery, announced that Nanette Cocero, Ph.D., has been appointed to its Board of Directors.
PharmaJet® announced that its Tropis® System is now the exclusive intradermal delivery system for two authorized novel Covid-19 vaccines: This press release features multimedia.
PharmaJet,® a company engineering Precision Delivery Systems™ that overcome the challenges of vaccines and pharmaceuticals delivery, announced that Marie Mazur, PharmD, has been appointed Chair of the Board of Directors.
PharmaJet®, a company engineering precision delivery systems that overcome the challenges of vaccine delivery, announced their support for the World Health Organization’s polio eradication campaigns in Pakistan starting in May 2023.
PharmaJet,® a company engineering Precision Delivery Systems™ that may overcome the challenges of vaccines and pharmaceuticals delivery announced that Nathalie Landry, has been appointed Chief Scientific Officer.
PharmaJet Announces U.S. Government Award Expansion to Clinically Assess a DNA Vaccine Combined with its Systems
PharmaJet® announced that it received a scope expansion and 3-year extension of its multi-year agreement with the Joint Science and Technology Office of the U.S. Defense Threat Reduction Agency.
Review Highlights Growing Evidence That PharmaJet’s Precision Delivery Devices Improve Nucleic Acid Vaccine Performance
In a review article recently published in Vaccines Journal, Dr. Carmen Ledesma-Feliciano, Scientific Affairs Manager at PharmaJet, referencing over 25 studies, discusses multiple injection delivery methods including PharmaJet’s needle-free precision delivery systems, which enhance the clinical performance of DNA-based vaccines.
In the near future, painful jabs and muscle soreness that persists for days could be replaced by new immunization approaches including intradermal delivery, edible and intranasal vaccines.
On World Polio Day 2022, PharmaJet Announces $1.5 million Grant From USAID to Evaluate Use of Needle-Free Delivery in Routine Polio Immunization
PharmaJet® announced they received a multi-year, $1.5 million grant from the United States Agency for International Development, to evaluate the impact of intradermal vaccine administration using their Tropis® Needle-free Injection System.
PharmaJet to Present Latest Research Showing Superior Immunogenicity with Their Needle-free Systems at Five Conferences in October
PharmaJet today announced that their latest research results will be presented at five upcoming conferences in October.
PharmaJet Presents Multiple Partners’ Data Demonstrating Superior Immunogenicity With Their Needle-free Systems at BIO International Convention
PharmaJet®, a biotech company that, with their innovative needle-free technology has developed a more effective way of administering drugs and biologics to accelerate research, commercialization and public health outcomes, announced that their latest research results were presented at the BIO International Convention in June.
PharmaJet® announced that Darin Zehrung has joined the executive leadership team as Chief Business Development Officer.
PharmaJet Presents Partner Data Demonstrating Superior Immunogenicity With Their Needle-free Systems at World Vaccine Congress
PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced that their latest research results were presented at the World Vaccine Congress on April 20.
Covestro, a leading polymer company, is proud to announce its collaboration with PharmaJet, a leading biotech company in needle-free injection technology.
PharmaJet® announced the release of a video highlighting the recent implementation of a polio vaccination campaign in Somalia.
PharmaJet® announced that their poster will be presented on March 1-3, 2022 at the Vaccination Acceptance Research Network conference, sponsored by the Sabin Vaccine Institute.
PharmaJet partner Zydus Cadila Announces COVID-19 Vaccine Expansion Plan to Multiple Countries With Korean Firm
PharmaJet®, the maker of innovative, needle-free injection technology, announced that its partner Zydus Cadila, is partnering with Enzychem Lifesciences to manufacture their COVID-19 plasmid DNA vaccine in Korea.
PharmaJet Presents How to Improve Vaccine Performance with Needle-free Delivery at Vaccine World Asia Congress
PharmaJet®, the maker of innovative, needle-free injection technology, announced that their latest research results will be presented at the Vaccine World Asia Congress 2021 on November 17.
PharmaJet®, the maker of innovative, needle-free injection technology, announced that its Tropis® intradermal needle-free injection system is being used in a campaign in Somalia delivering inactivated polio vaccine to more than 110,000 children.
PharmaJet today announced that patient enrollment has started for the phase 1 trial in Australia using its Needle-free Injection Systems to deliver a vaccine against SARS-CoV-2.